European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Date of authorisation: 29/09/2000, Revision: 58, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:56

Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Date of authorisation: 29/09/2000, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:55

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ilumira, lutetium (177Lu) chloride, Date of authorisation: 26/03/2026, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:45

Human medicines European public assessment report (EPAR): Ilumira, lutetium (177Lu) chloride, Date of authorisation: 26/03/2026, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:20

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation: 23/07/2012, Revision: 34, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:12

Human medicines European public assessment report (EPAR): Fycompa, perampanel, Date of authorisation: 23/07/2012, Revision: 34, Status: Authorised

Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 April 2026, 15:00 (CEST) to 24 April 2026, 17:00 (CEST)

Submitted by Anonymous (not verified) on 1 April 2026 - 16:07

Breakthrough medical devices: information session, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 April 2026, 15:00 (CEST) to 24 April 2026, 17:00 (CEST)

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 49, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:04

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 28, Status: Authorised

Submitted by Anonymous (not verified) on 1 April 2026 - 16:02

Human medicines European public assessment report (EPAR): Firazyr, icatibant, Date of authorisation: 11/07/2008, Revision: 28, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More